Our Lion of Small Cap
|Written by GSCR Staff|
|Friday, 30 January 2015 06:49|
Last week and again in Monday’s Goldman Guide we thought some of the mega cap financial reports yesterday would calm the market nerves.
Big misses and lowered expectations on names like The Proctor & Gamble Company (NYSE – PG) and especially Microsoft Corporation (NASDAQ – MSFT) had the opposite effect. Apple Inc. (NASDAQ – AAPL) saved the day and the market had a subtle bounce back. What does this say about us as consumers? Do we care more about our hip gadgets than our shampoo? Just a thought, but we digress…
In any event we thought we would revisit biotech, our lion, in the small cap sector, if you will. The small cap biotech sector has been on a solid tear over the last 24 months as indicated by the chart for PowerShares S&P SmallCap Health Care ETF (NASDAQ - PSCH), which we will use as a proxy.
2-Year Chart for PSCH
Our candidate for today is Lion Biotechnologies, Inc. (NASDAQ – LBIO - $7.97). Lion Biotechnologies is a development stage biotechnology company that develops T-cells and engineered T-cells for the treatment of various cancers. The Company’s lead product candidate includes a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop and manufacture certain proprietary autologous TILs adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer.
We should note that the technical indicators are very strong long term as illustrated by the EMA and news from the pipeline has been upbeat recently as well. In December,Lion presented positive new data from a Phase II clinical trial of TIL therapy in metastatic melanoma at the American Society of Hematology (ASH) annual meeting in San Francisco, CA. Earlier this month the Company filed an investigational new drug (IND) application with the FDA to conduct a Phase 2 clinical trial of the Company's lead product candidate, LN-144, in the treatment of patients with refractory metastatic melanoma. LN-144 is a cell product of autologous tumor infiltrating lymphocytes (TIL) derived from the patient's tumor.
With over $17 million in cash Lion Biotechnologies is positioned to maintain its pipeline for research provided cash flow remains steady from new investors and road shows. LBIO should climb back up to 52-week high range of $11 by the end of 2Q15.
Have a great day!
Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours.
This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small CapResearch blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLECONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLECONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com
Leave your comments